# A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

> **NCT07717411** · PHASE3 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 1600 (estimated)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Trontinemab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07717411
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-11-30
- **Primary completion:** 2032-09-03
- **Final completion:** 2032-09-03
- **Target enrollment:** 1600 (ESTIMATED)
- **Last updated:** 2026-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717411, "A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*